vs
Jaguar Health, Inc.（JAGX）与Rithm Property Trust Inc.（RPT）财务数据对比。点击上方公司名可切换其他公司
Rithm Property Trust Inc.的季度营收约是Jaguar Health, Inc.的1.1倍（$3.4M vs $3.2M），Rithm Property Trust Inc.净利率更高（95.4% vs -717.2%，领先812.6%），Jaguar Health, Inc.同比增速更快（-7.8% vs -39.7%），过去两年Jaguar Health, Inc.的营收复合增速更高（17.3% vs -43.2%）
Jaguar Health, Inc.是一家处于商业化阶段的生物制药企业，专注于开发和商业化植物源处方药物，覆盖人用和动物用两大领域，核心管线针对胃肠道领域未被满足的医疗需求，主要市场覆盖北美及部分欧洲区域。
Rithm Property Trust Inc.旗下的里思资本是一家总部位于纽约的美国投资管理公司，核心业务聚焦于房地产投资及另类投资领域，是该赛道颇具影响力的专业投资机构。
JAGX vs RPT — 直观对比
营收规模更大
RPT
是对方的1.1倍
$3.2M
营收增速更快
JAGX
高出31.9%
-39.7%
净利率更高
RPT
高出812.6%
-717.2%
两年增速更快
JAGX
近两年复合增速
-43.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2M | $3.4M |
| 净利润 | $-23.2M | $3.2M |
| 毛利率 | 32.0% | — |
| 营业利润率 | -656.6% | 99.6% |
| 净利率 | -717.2% | 95.4% |
| 营收同比 | -7.8% | -39.7% |
| 净利润同比 | -133.9% | 11.2% |
| 每股收益（稀释后） | $10.27 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAGXRPT
| Q4 25 | $3.2M | $3.4M | ||
| Q3 25 | $3.1M | $4.0M | ||
| Q2 25 | $3.0M | $4.2M | ||
| Q1 25 | $2.2M | $249.0K | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $3.1M | — | ||
| Q2 24 | $2.7M | — | ||
| Q1 24 | $2.4M | — |
净利润JAGXRPT
| Q4 25 | $-23.2M | $3.2M | ||
| Q3 25 | $-9.5M | $-273.0K | ||
| Q2 25 | $-10.4M | $1.9M | ||
| Q1 25 | $-10.5M | $-3.4M | ||
| Q4 24 | $-9.9M | — | ||
| Q3 24 | $-9.9M | — | ||
| Q2 24 | $-9.5M | — | ||
| Q1 24 | $-9.2M | — |
毛利率JAGXRPT
| Q4 25 | 32.0% | — | ||
| Q3 25 | 82.7% | — | ||
| Q2 25 | 82.3% | — | ||
| Q1 25 | 76.7% | — | ||
| Q4 24 | 84.1% | — | ||
| Q3 24 | 82.6% | — | ||
| Q2 24 | 84.3% | — | ||
| Q1 24 | 81.7% | — |
营业利润率JAGXRPT
| Q4 25 | -656.6% | 99.6% | ||
| Q3 25 | -234.8% | -6.2% | ||
| Q2 25 | -268.8% | 45.7% | ||
| Q1 25 | -425.5% | -1416.5% | ||
| Q4 24 | -232.5% | — | ||
| Q3 24 | -233.7% | — | ||
| Q2 24 | -264.5% | — | ||
| Q1 24 | -349.4% | — |
净利率JAGXRPT
| Q4 25 | -717.2% | 95.4% | ||
| Q3 25 | -308.2% | -6.8% | ||
| Q2 25 | -349.3% | 45.1% | ||
| Q1 25 | -472.6% | -1363.1% | ||
| Q4 24 | -282.7% | — | ||
| Q3 24 | -317.1% | — | ||
| Q2 24 | -348.8% | — | ||
| Q1 24 | -392.4% | — |
每股收益（稀释后）JAGXRPT
| Q4 25 | $10.27 | $-0.26 | ||
| Q3 25 | $-6.28 | $-0.03 | ||
| Q2 25 | $-10.26 | $0.01 | ||
| Q1 25 | $-16.70 | $-0.08 | ||
| Q4 24 | $-14.62 | — | ||
| Q3 24 | $-1.05 | — | ||
| Q2 24 | $-4.04 | — | ||
| Q1 24 | $-0.06 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $968.0K | $79.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-18.7M | $291.6M |
| 总资产 | $38.3M | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资JAGXRPT
| Q4 25 | $968.0K | $79.3M | ||
| Q3 25 | $3.5M | $81.4M | ||
| Q2 25 | $2.2M | $98.6M | ||
| Q1 25 | $5.7M | $97.4M | ||
| Q4 24 | $8.0M | — | ||
| Q3 24 | $13.3M | — | ||
| Q2 24 | $16.0M | — | ||
| Q1 24 | $11.7M | — |
股东权益JAGXRPT
| Q4 25 | $-18.7M | $291.6M | ||
| Q3 25 | $4.4M | $291.7M | ||
| Q2 25 | $6.9M | $294.7M | ||
| Q1 25 | $830.0K | $296.1M | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $13.1M | — | ||
| Q2 24 | $16.6M | — | ||
| Q1 24 | $11.8M | — |
总资产JAGXRPT
| Q4 25 | $38.3M | $1.0B | ||
| Q3 25 | $49.5M | $1.0B | ||
| Q2 25 | $48.3M | $1.0B | ||
| Q1 25 | $51.5M | $1.0B | ||
| Q4 24 | $53.4M | — | ||
| Q3 24 | $58.5M | — | ||
| Q2 24 | $61.5M | — | ||
| Q1 24 | $55.4M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.5M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -2.56× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流JAGXRPT
| Q4 25 | $-5.5M | $-8.3M | ||
| Q3 25 | — | $-5.8M | ||
| Q2 25 | — | $-25.0K | ||
| Q1 25 | $-7.3M | $-1.6M | ||
| Q4 24 | $-7.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-7.0M | — |
现金转化率JAGXRPT
| Q4 25 | — | -2.56× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAGX
| Human Health Segment | $3.2M | 97% |
| Other | $83.0K | 3% |
RPT
暂无分部数据
